Article Dans Une Revue Critical Care Année : 2026

Amikacin pharmacokinetics after nebulization among intubated patients

Résumé

Background: Amikacin nebulization may be used in mechanically ventilated patients for pneumonia prevention and treatment. Available drug delivery and pharmacokinetic knowledge mainly rely on in vitro data and studies of a limited number of patients. Methods: To evaluate pulmonary and systemic pharmacokinetics of nebulized amikacin in mechanically ventilated patients and assess the influence of ventilation and nebulization conditions on drug concentrations in the tracheal aspirate and plasma. This ancillary study of a published randomized trial performed population pharmacokinetic modelling on 498 tracheal aspirates and 602 plasma concentrations following 20 mg/kg amikacin vibrating mesh nebulization among 261 patients.

Results: Tracheal aspirate amikacin concentrations were very high but variable between patients (median peak concentration 7269 µg/g, interquartile range 4935-9846 µg/g). The tracheal aspirate concentration declined with a median terminal half-life of 7.6 hours (interquartile range

Fichier principal
Vignette du fichier
s13054-026-05965-3_reference.pdf (1.82 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Licence

Dates et versions

inserm-05605117 , version 1 (28-04-2026)

Licence

Identifiants

Citer

Nicolas Grégoire, Sandrine Marchand, François Barbier, Jean-Pierre Quenot, Jean-Etienne Herbrecht, et al.. Amikacin pharmacokinetics after nebulization among intubated patients. Critical Care, 2026, ⟨10.1186/s13054-026-05965-3⟩. ⟨inserm-05605117⟩
9 Consultations
2 Téléchargements

Altmetric

Partager

  • More